<DOC>
	<DOCNO>NCT01633281</DOCNO>
	<brief_summary>A significant proportion ( 60 % ) myeloma patient treat Bortezomib thalidomide develop significant peripheral neuropathy ( PN ) . Standard care complication include drug like gabapentin pregabalin , relieve symptom partially . PN grade II mandate reduction dose frequency Bortezomib thalidomide , may compromise treatment outcome . This clinical study explore whether , intervene early course use acupuncture , progression PN reverse , stabilize retard thereby allow continuation treatment schedule .</brief_summary>
	<brief_title>Acupuncture Peripheral Neuropathy</brief_title>
	<detailed_description>1 . The acupuncture treatment start patient receive least 3 week Gabapentin Pregabalin adequate dose without improvement PN 2 . Two session acupuncture per week , 30minutes duration , administer total 10 session 5 week . The needle do designated acupuncturist patient , delivered electrical stimulation define frequency . 3 . A fixed set acupoints apply include local distant point , base symptom PN classification TCM syndrome . Some degree flexibility addition reduction acupoints allow base clinical indication . The acupoints needle session record . 4 . Assessment efficacy 4.1 Objective response : A complete neurological examination do commencement acupuncture end acupuncture . In addition , full nerve conduction test do begin acupuncture end 10 session acupuncture . 4.2 Subjective assessment A quality life questionnaire ( FACT/GOG-NTX v4 ) fill patient enrolment , commencement , 6th session end 10 session acupuncture . 4.3 Scoring With objective subjective assessment , Total Neuropathy Score calculate time point quantitative measurement severity PN 5 . Statistical consideration The statistical analysis specifies low limit two-sided 90 percent confidence interval overall positive response exceed 10 percent would consider evidence significant efficacy acupuncture retard Bortezomib thalidomide induce PN . Allowing confidence interval width 30 % , sample size need 34 patient . To allow 10 % drop-out , plan recruit total 40 patient</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Age &gt; 21 year diagnosis plasma cell dyscrasia lymphoma . 2 . Patients must neuropathy great equal 2 accord CTCAE v 3.0 scale spite adequate duration ( least 3 week ) previous treatment Gabapentin Pregabalin unable tolerate drug . Patients receive drug must remain medication throughout study period ; however , minor adjustment dosage allow . 3 . The patient 's current previous treatment must include bortezomib thalidomide 4 . ECOG Performance Status 0 , 1 , 2 1 . Local infection near acupuncture site . ( Although acupuncture minimally invasive procedure , patient exclude indication active infection . ) 2 . Thrombocytopenia ( platelet count &lt; 50x 109/L ) day acupuncture session 3 . Deformities could interfere accurate acupuncture point location energy pathway define traditional acupuncture theory . 4 . Concurrent use anticoagulation agent . 5 . Known coagulopathy take heparin ( include low molecular weight heparin ) warfarin dose . Patients aspirin nonsteroidal antiinflammatories allow participate . 6 . Persistent absolute neutrophil count &lt; 1 x 109/L 7 . Active CNS disease . 8 . Patients cardiac pacemaker . 9 . Currently pregnant lactating female . 10 . Severe diabetic neuropathy neuropathy relate HIV . 11 . Previous acupuncture treatment indication within 30 day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>peripheral neuropathy</keyword>
	<keyword>acupuncture</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Thalidomide</keyword>
</DOC>